Markets:

Overview

News

Currencies

International

Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.420 -0.070 (-4.70%)

Streaming Delayed Price Updated: 10:30 AM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 04, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

July 31, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference

July 29, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

July 28, 2025

Via Benzinga

INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? ↗

July 28, 2025

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

Via Benzinga

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

July 24, 2025

From INmune Bio, Inc.

Via GlobeNewswire

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday ↗

July 04, 2025

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

Via Benzinga

Which stocks have an unusual volume on Thursday? ↗

July 03, 2025

The trading volume of these stocks is deviating from the norm in today's session.

Via Chartmill

This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

July 01, 2025

Via Benzinga

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 30, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Let's take a look at the stocks that are in motion in today's session. ↗

June 30, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Crude Oil Moves Lower; Joby Aviation Shares Surge ↗

June 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 30, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

June 30, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain ↗

June 30, 2025

INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint.

Via Benzinga

Dow Gains Over 100 Points; Chicago PMI Weakens In June ↗

June 30, 2025

Via Benzinga

Topics Stocks

Gapping stocks in Monday's session ↗

June 30, 2025

The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial ↗

June 30, 2025

The primary endpoint of the study was not met in the intent-to-treat population, the company said.

Via Stocktwits

Get insights into the top gainers and losers of Monday's pre-market session. ↗

June 30, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 30, 2025

Via Benzinga

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

June 30, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket ↗

June 30, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

June 27, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 27, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes ↗

June 27, 2025

INmune Bio stock rose sharply on high volume ahead of topline Phase 2 trial data for XPro in early Alzheimer's, expected on June 30.

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

June 27, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

June 27, 2025

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 27, 2025

Via Benzinga

INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week ↗

June 27, 2025

INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 26, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.